AstraZeneca to supply 400 million of potential vaccine to Europe

▴ astrazeneca-supply-400-million-potential-vaccine-europe
Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon

UK Pharma company AstraZeneca Plc has come in a contract with European governments to provide its potential vaccine against the Coronavirus to assist combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company reportedly said on Saturday, adding that it had been looking to expand the manufacturing of the vaccine, which it said it might provide for no profit during the pandemic. The vaccine remains in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start out by 2020 end.
The deal thus inscribes that Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon.

"This will make sure that hundreds of millions of people in Europe will have access to the present vaccine, in fact, if it works and that we will know that by summer-end," the company's chief executive, Pascal Soriot was quoted as saying to the journalists. He said he has "good hope" that it'll work, supported initial data.
The alliance "will work alongside the European Commission and other countries in Europe to make sure everybody across Europe is provided with the vaccine," he said.
"We have a really self-sufficient supply chain for Europe" with manufacturers lined up within the Netherlands, Germany, Italy, and Italy, among others, he further said.


The vaccines are for all EU member states. The four nations that agreed the deal can pay for the entire amount, which has not been disclosed, and therefore the scheme allows other countries to hitch it under equivalent conditions, a source from the Italian health ministry said.
Apparently, China, Brazil, Japan, and Russia have also shown interest in this vaccine.
It has got the green signal from The British Medicines and Healthcare products regulatory authority (MHRA) kick start the phase III clinical trial of the vaccine after studies suggest sufficient efficacy and safety, Soriot reportedly said.
At a gathering of EU Health Ministers on Friday, IVA apparently agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
It has agreed on the manufacturing of manufacturing 2 billion doses of the vaccine to serve its target beneficiaries along with two Bill Gates-backed ventures and a $1.2 billion agreement with the United States government.
The deal will add an extra 100 million doses to the two billion already committed by the group, AstraZeneca said.
There are not any approved vaccines or treatments for COVID-19, the highly contagious respiratory disease caused by the novel coronavirus.
"Many countries within the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a gaggle of member states will create added value for all EU citizens during this crisis," Italian Health Minister Roberto Speranza was quoted as saying

Tags : #Coronavirus #Vaccine #Astrazeneca #Europe #China #Brazil #BillGates

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Tier-2 and Tier-3 Cities: India's Next Big Healthcare Growth StorySeptember 18, 2026
Why Regional Hospital Chains Are Becoming More Important in IndiaSeptember 18, 2026
The Future of Indian MedTech Exports: Can India Compete With Global Leaders?September 17, 2026
Robotic-Assisted Procedures Beyond Surgery: Where Is Automation Going Next in Healthcare?September 17, 2026
58 Students from SRM Medical College Selected for Union Government Research Programmes and Grants September 16, 2026
Handpickd Questions the Role of Science in Food with ‘Science-Less’ Newspaper CampaignSeptember 16, 2026
As Women’s Cancer Burden Rises, Integrated Care Emerges as The Next Frontier in Cancer TreatmentSeptember 16, 2026
Odia Superstar Babushaan Mohanty Inaugurates Manoj Das Library at Utkal Gaurav International SchoolSeptember 16, 2026
Yashoda Hospitals, Somajiguda Successfully Treats 10-Month-Old with Complex Heart Condition Through Staged ApproachSeptember 16, 2026
Tracky launches 16D, India's first 16-day continuous glucose monitoring system (CGM)September 16, 2026
Why Local Medical Device Manufacturing Matters for Indian HealthcareSeptember 16, 2026
Next-Generation Surgical Robots Entering the Indian Market: What It Means for Patients and ProvidersSeptember 16, 2026
ShardaCare - Healthcity Marks World Sepsis Day with Training for Over 50 NursesSeptember 15, 2026
From Empowerment to Ownership: Upasana Kamineni Konidela Calls for a BRICS Women’s Economic CorridorSeptember 15, 2026
WORLD HEART DAY 2026: Don't Miss a Beat: The Heart Attacks That Never Had to HappenSeptember 15, 2026
BL Agro Announces Investment of ₹1,500 Crore In Its Biotech-Arm Leads Genetics To Build An Integrated Dairy and Genetics EcosystemSeptember 15, 2026
Can You Have PMOS With Regular Periods? What Women Often Get WrongSeptember 15, 2026
Hospital Data Breaches in India: What Every Patient Needs to Know Right NowSeptember 15, 2026
Cybersecurity of ICUs: Protecting Connected Critical-Care Systems in Indian HospitalsSeptember 15, 2026
Fortis Hospital, Shalimar Bagh Becomes Delhi NCR’s First Multi-speciality Hospital to Launch Rezūm™ Water Vapor Therapy for Enlarged ProstateSeptember 14, 2026